Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis B
Biotech
Barinthus lays off 25%, sidelines prostate cancer program
Barinthus used positive data from a pair of phase 2 trials for its hepatitis B therapy as justification for jettisoning a quarter of its workforce.
James Waldron
Jun 13, 2024 5:30am
GSK signs AI pact with Ochre to pinpoint source of liver disease
Jun 12, 2024 9:25am
GSK sets diversity targets, partners with DEI firm for education
May 22, 2024 11:00am
Ascletis pulls FXR agonist from pipeline over phase 2 data
Apr 3, 2024 8:50am
Altimmune bails on hepatitis B after phase 2 data disappoint
Mar 27, 2024 7:57am
Brii punts HIV, depression, lung programs to potential partners
Mar 22, 2024 11:34am